CORT - A Noteworthy Decision By Atabak Mokari As Acquires $105K In Corcept Therapeutics Stock Options | Benzinga
A substantial insider move unfolded on February 14, as Mokari, Chief Financial Officer at Corcept Therapeutics (NASDAQ:CORT), reported the acquisition of stock options for 200,000 shares in an SEC filing.
What Happened: Disclosed in a Form 4 filing on Wednesday with the U.S. Securities and Exchange Commission, Mokari, Chief Financial Officer at Corcept Therapeutics, made a strategic derivative acquisition. This involved acquiring stock options for 200,000 shares of CORT, providing the right to buy the company's stock at an exercise price of $23.01 per share.
The latest update on Wednesday morning shows Corcept Therapeutics shares up by 2.13%, trading at $23.54. At this price, Mokari's 200,000 shares are worth $105,999.
Unveiling the Story Behind Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Financial Insights: Corcept Therapeutics
Revenue Growth: Corcept Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 21.5%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the ...